{"filing":{"accession_number":"0001193125-26-390535","cik":"0001877184","ticker":"KMTS","company_name":"KESTRA MEDICAL TECHNOLOGIES, LTD.","form":"8-K","filing_date":"2026-09-14","report_date":"2026-09-14","primary_document":"ck0001877184-20260914.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1877184/000119312526390535/ck0001877184-20260914.htm"},"events":[{"id":33249,"run_id":30570,"accession_number":"0001193125-26-390535","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing quarterly financial results for the first quarter of fiscal 2027 ended July 31, 2026. The filing explicitly states in Item 2.02 that \"Kestra Medical Technologies, Ltd. (the 'Company') issued a press release announcing its financial results for the fiscal quarter ended July 31, 2026,\" with the press release furnished as Exhibit 99.1. The disclosure includes revenue of $31.0 million (60% growth), gross margin expansion to 56.5%, and updated FY27 revenue guidance to $141 million (48% growth), all material metrics for investor assessment.","company_name":"KESTRA MEDICAL TECHNOLOGIES, LTD.","ticker":"KMTS","filing_date":"2026-09-14","form":"8-K","submitted_at":null,"items":[{"id":36645,"accession_number":"0001193125-26-390535","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing quarterly financial results for the first quarter of fiscal 2027 ended July 31, 2026. The filing explicitly states in Item 2.02 that \"Kestra Medical Technologies, Ltd. (the 'Company') issued a press release announcing its financial results for the fiscal quarter ended July 31, 2026,\" with the press release furnished as Exhibit 99.1. The disclosure includes revenue of $31.0 million (60% growth), gross margin expansion to 56.5%, and updated FY27 revenue guidance to $141 million (48% growth), all material metrics for investor assessment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T20:05:38.804987+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36645,"accession_number":"0001193125-26-390535","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing quarterly financial results for the first quarter of fiscal 2027 ended July 31, 2026. The filing explicitly states in Item 2.02 that \"Kestra Medical Technologies, Ltd. (the 'Company') issued a press release announcing its financial results for the fiscal quarter ended July 31, 2026,\" with the press release furnished as Exhibit 99.1. The disclosure includes revenue of $31.0 million (60% growth), gross margin expansion to 56.5%, and updated FY27 revenue guidance to $141 million (48% growth), all material metrics for investor assessment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T20:05:38.804987+00:00","company_name":"KESTRA MEDICAL TECHNOLOGIES, LTD.","ticker":"KMTS","filing_date":"2026-09-14"}]}